Smooth seas do not make skillful sailors
Cancer is a very heterogeneous disease, both clinically and biologically. In the last decade, the survival of cancer patients has been improved thanks to the introduction of targeted therapies. Even so, there are still patients who do not respond to current treatments or who develop resistance. Therefore, it is necessary to classify cancer in subgroups, identify predictive biomarkers of response and new therapeutic targets to combat resistance to current treatments.
The group uses genomic and molecular data to guide the design of clinical trials and the development of biomarkers (elements that allow for the evaluation of the response to a drug). Based on preclinical cancer models, it studies molecular mechanisms of sensitivity and pharmacological resistance. All this should help it identify better treatments for patients with solid tumours.
The approach starts from the observations obtained in patients: the group moves them to the laboratory, where it analyses them in detail to identify new biomarkers and therapies. Promising preclinical results give rise to new clinical trials, so the group returns to the clinical practice in which it explores whether these promising results are really valid for the patients.
Thanks to these studies, it hopes to obtain more personalised treatments for patients with cancer.